📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: Kinarus

1.1 - Company Overview

Kinarus Logo

Kinarus

Headquarter: Switzerland
Founded: 20XX🔒
Employees: 100-500🔒

Company description

  • Provider of biopharmaceutical therapies targeting stress-related inflammatory processes. Develops KIN001, a pamapimod/pioglitazone combination with anti-inflammatory, anti-fibrotic, and antiviral activities, in Phase 2 trials for hospitalized COVID-19 (acute and long-term), wet AMD (reducing anti-VEGF injection frequency), and IPF (reducing lung fibrosis).

Products and services

  • KIN001: A combination therapy of pamapimod and pioglitazone that targets viral, respiratory, and ophthalmic diseases by leveraging anti-inflammatory, anti-fibrotic, and antiviral activities
  • Phase 2 Clinical Trial for COVID-19: A large-scale study evaluating KIN001’s efficacy in hospitalized patients, addressing both acute symptoms and long-term consequences of COVID-19
  • Phase 2 Clinical Trial for IPF: A study evaluating KIN001’s effectiveness in idiopathic pulmonary fibrosis patients, aiming to reduce lung fibrosis

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to Kinarus

Vicore Pharma Logo

Vicore Pharma

HQ: Sweden Website
  • Description: Provider of pharmaceuticals for severe lung disorders, developing drugs acting through the angiotensin II type 2 (AT2) receptor, including buloxibutid (C21), an orally available ATRAG in phase 2a for idiopathic pulmonary fibrosis (IPF) with orphan drug designation in the EU, and Almee, a digital therapeutic based on cognitive behavioral therapy to address the psychological impact of pulmonary fibrosis.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Vicore Pharma company profile →
Mavu Pharma Logo

Mavu Pharma

HQ: United States Website
  • Description: Provider of non-nucleotide, conditional modulators of the STING pathway to treat cancer and infectious disease.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Mavu Pharma company profile →
Sanofi Logo

Sanofi

HQ: France Website
  • Description: Provider of prescription drugs, vaccines, and treatments for chronic, rare, and infectious diseases, offering research, development, manufacturing, and marketing of innovative therapeutic solutions across diabetes care, human vaccines, innovative drugs, consumer healthcare (OTC for allergies, cough, cold, flu, digestive wellness), pain care, physical & mental wellness, patient engagement, emerging markets, animal health, and the new G enzyme.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Sanofi company profile →
UPSA Logo

UPSA

HQ: France Website
  • Description: Provider of pharmaceuticals, food supplements, and medical devices for the fight against pain and self-medication, serving patients from infants to seniors.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full UPSA company profile →
DJS Antibodies Logo

DJS Antibodies

HQ: United Kingdom Website
  • Description: Provider of antibody therapeutics and discovery technology targeting GPCRs to treat chronic inflammatory and fibrotic diseases. Offers HEPTAD, a proprietary platform to discover functional, first-in-class antibodies for complex protein targets; DJS 001, a first-in-class program for myeloid cell driven inflammatory disease; and DJS 002, a monoclonal antibody for fibrotic diseases without off-target side effects.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full DJS Antibodies company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for Kinarus

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Kinarus

2.2 - Growth funds investing in similar companies to Kinarus

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for Kinarus

4.2 - Public trading comparable groups for Kinarus

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to Kinarus

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About Kinarus

What does Kinarus do?

Kinarus is a provider of biopharmaceutical therapies targeting stress-related inflammatory processes. Develops KIN001, a pamapimod/pioglitazone combination with anti-inflammatory, anti-fibrotic, and antiviral activities, in Phase 2 trials for hospitalized COVID-19 (acute and long-term), wet AMD (reducing anti-VEGF injection frequency), and IPF (reducing lung fibrosis).

Who are Kinarus's competitors?

Kinarus's competitors and similar companies include Vicore Pharma, Mavu Pharma, Sanofi, UPSA, and DJS Antibodies.

Where is Kinarus headquartered?

Kinarus is headquartered in Switzerland.

How many employees does Kinarus have?

Kinarus has 1,000 employees 🔒.

When was Kinarus founded?

Kinarus was founded in 2010 🔒.

What sector and industry vertical is Kinarus in?

Kinarus is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for Kinarus

Who are the top strategic acquirers in Kinarus's sector and industry

Top strategic M&A buyers and acquirers in Kinarus's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for Kinarus?

Top strategic M&A buyers groups and sectors for Kinarus include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in Kinarus's sector and industry vertical

Which are the top PE firms investing in Kinarus's sector and industry vertical?

Top PE firms investing in Kinarus's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in Kinarus's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Kinarus's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in Kinarus's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Kinarus include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in Kinarus's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Kinarus?

The key public trading comparables and valuation benchmarks for Kinarus include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for Kinarus for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Kinarus with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Kinarus's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Kinarus with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Kinarus's' sector and industry vertical?

Access recent funding rounds and capital raises in Kinarus's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Kinarus